Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.

Related Keywords

Costanza Alciati , , Bio Developments , Pipelines , Emerging Markets , Glp 1 , Eli Lilly , Novo Nordisk , Obesity , Clinical Trial ,